CORRECTION: Silence Therapeutics Q3 EPADS $(0.45) Misses $(0.28) Estimate, Sales $159.000K Miss $4.414M Estimate

Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.28) by 60.71 percent. This is a 80 percent decrease over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $159.000 thousand which missed the analyst consensus estimate of $4.414 million by 96.40 percent. This is a 89.39 percent decrease over sales of $1.498 million the same period last year.